search
Back to results

Chinese Cancer Prevention Study(CHICAPS) (CHICAPS)

Primary Purpose

Cervical Intraepithelial Neoplasia, Cervical Cancer, Cervical Neoplasm

Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
cryotherapy
Colposcopy
Sponsored by
Preventive Oncology International, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Cervical Intraepithelial Neoplasia focused on measuring community based participatory research

Eligibility Criteria

35 Years - 59 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

Inclusion Criteria

  1. Non pregnant women 35-59 years of age.
  2. No hysterectomy
  3. No prior pelvic radiation.
  4. Willing to sign consent form

Exclusion Criteria:

  1. Males
  2. Women younger than 35 years old and older than 59 years old.
  3. Pregnant women.
  4. Patients with known history of hysterectomy or radiation for a pelvic cancer.
  5. Refusal to participate

Sites / Locations

  • HeShan Public Health Department

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Cryotherapy after VIA triage

Colposcopy and biopsy

Arm Description

Women who test HPV positive will be randomized to the experimental arm or the standard of care arm. In the Experimental arm VIA will be done to determine acceptability for cryotherapy [R/O high-grade CIN too large for cryotherapy (usually 3-4 quadrant disease) or cancer]. All acceptable patients will have an ECC done and then immediate cryotherapy.

Standard of care. Women testing positive for HPV will be randomized to the experimental arm (immediate cryotherapy) or the Standard of care arm, for colposcopy, biopsy, and leep based on the pathology results.

Outcomes

Primary Outcome Measures

The investigators will determine the percentage of the population in the target area that are reached by the screening protocol.
Pilot study will take up to 8 months. The community application will be complete approximately 5 months later and all follow up and data analysis will be complete in 36 months.
The investigators will determine the percentage of HPV screen positive women who return for evaluation and treatment.
Pilot study will take up to 8 months. The community application will be complete approximately 5 months later and all follow up and data analysis will be complete in 36 months

Secondary Outcome Measures

The investigators will compare women treated in the standard of care arm and the experimental arm (VIA and cryotherapy) to determine the percentage of high grade disease at the 6 month follow-up and 2 year follow-up.
Pilot study will take up to 8 months. The community application will be complete approximately 5 months later and all follow up and data analysis will be complete in 36 months

Full Information

First Posted
December 29, 2011
Last Updated
May 6, 2015
Sponsor
Preventive Oncology International, Inc.
Collaborators
Peking University Shenzhen Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT01524003
Brief Title
Chinese Cancer Prevention Study(CHICAPS)
Acronym
CHICAPS
Official Title
Chinese Cancer Prevention Study(CHICAPS) Mass Population Based Cervical Cancer Screening
Study Type
Interventional

2. Study Status

Record Verification Date
May 2015
Overall Recruitment Status
Completed
Study Start Date
November 2011 (undefined)
Primary Completion Date
July 2013 (Actual)
Study Completion Date
January 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Preventive Oncology International, Inc.
Collaborators
Peking University Shenzhen Hospital

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to develop and implement a community based preventive healthcare model using cervical cancer screening as the target medical intervention. The investigators will first conduct 2 pilot studies to refine their preventive healthcare model based on the principles of community based participatory research (1000 participants). The investigators will then apply the model to screen 9000 women for cervical cancer over a period of 7-9 days. This 10,000 patient trial will explore the ability of a community to conduct their own screening program to identify who needs medical intervention based on self-collection and centralized high-throughput low cost human papillomavirus (HPV) testing.
Detailed Description
Screening and prevention programs in general, throughout the world, suffer from major cost constraints, poor participation, lost to follow-up, and concerns about sustainability. Over the past 15 years the investigators have been studying self-collection as a way to reach the medically underserved for cervical cancer screening. In a recent 10,000 patient randomized clinical trial they demonstrated that a self-collected sample is equivalent in accuracy to a physician obtained endocervical specimen and can be done less expensively and with higher throughput than all current and proposed accurate testing modalities. With the majority of the worlds' medically underserved now living in middle income countries, it is no longer necessary to think small, slow, and simple, with poor quality control. It is totally achievable with self-collection to have centralized, high-throughput, low cost per case processing, and to reach millions of women in a short period of time. Again, these concepts need not be restricted to the medically underserved, but the clarity of this paradigm is a realistic solution for a critical developing world healthcare problem. In addition, we now have solid media specimen transport cards, thereby avoiding the logistics of dealing with personal use of alcohol-based liquids, concerns about exposure temperature, and ease of transportation. Using PCR-based technologies in a self-collection algorithm has the ability to not only make the testing highly sensitive, but help to address another key issue and that is how to manage the positives. In the investigators' proposed centralized model, since the primary output of the testing provides genotyping a reasonable option for tailoring the management of the positives would exist. Now the need is to focus on developing the models that will enable them to efficiently place the existing technologies next to the women who need them the most. Developing community based systems that remove the identification of who is abnormal from the medical model, will markedly affect the cost of preventive healthcare. In addition with community involvement in the design of the program, it is expected that their participation in the "campaigns" and follow-up will be significantly improved. Sustainability also becomes a simpler problem because of the "campaign" or "event" type model (possibly once/year, or per every 5-10years). The investigators believe that the patient recruitment and loss to follow up observed in screening programs conducted in the developing world, have their roots in asking large numbers of patients, who are not presently ill, or symptomatic, to travel long distances and interrupt their daily life. The investigators believe that a much more effective program can be designed by the community, and using a self-collection model will ensure greater recruitment and participation, minimizing loss to follow up. This project CHICAPS is designed to further develop the community based screening model and in addition randomize treatment options to explore a technology more suited to rural environments

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cervical Intraepithelial Neoplasia, Cervical Cancer, Cervical Neoplasm, Cervical Dysplasia, Human Papillomavirus
Keywords
community based participatory research

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
8382 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cryotherapy after VIA triage
Arm Type
Experimental
Arm Description
Women who test HPV positive will be randomized to the experimental arm or the standard of care arm. In the Experimental arm VIA will be done to determine acceptability for cryotherapy [R/O high-grade CIN too large for cryotherapy (usually 3-4 quadrant disease) or cancer]. All acceptable patients will have an ECC done and then immediate cryotherapy.
Arm Title
Colposcopy and biopsy
Arm Type
Active Comparator
Arm Description
Standard of care. Women testing positive for HPV will be randomized to the experimental arm (immediate cryotherapy) or the Standard of care arm, for colposcopy, biopsy, and leep based on the pathology results.
Intervention Type
Procedure
Intervention Name(s)
cryotherapy
Other Intervention Name(s)
MedGyn cryotherapy, medical grade CO2
Intervention Description
cryotherapy treatment of the uterine cervix
Intervention Type
Procedure
Intervention Name(s)
Colposcopy
Other Intervention Name(s)
Digital colposcopy, POI microbiopsy, LEEP
Intervention Description
Colposcopy, biopsy and LEEP based on the pathology results
Primary Outcome Measure Information:
Title
The investigators will determine the percentage of the population in the target area that are reached by the screening protocol.
Description
Pilot study will take up to 8 months. The community application will be complete approximately 5 months later and all follow up and data analysis will be complete in 36 months.
Time Frame
Ongoing for up to 36 months
Title
The investigators will determine the percentage of HPV screen positive women who return for evaluation and treatment.
Description
Pilot study will take up to 8 months. The community application will be complete approximately 5 months later and all follow up and data analysis will be complete in 36 months
Time Frame
Ongoing for up to 36 months
Secondary Outcome Measure Information:
Title
The investigators will compare women treated in the standard of care arm and the experimental arm (VIA and cryotherapy) to determine the percentage of high grade disease at the 6 month follow-up and 2 year follow-up.
Description
Pilot study will take up to 8 months. The community application will be complete approximately 5 months later and all follow up and data analysis will be complete in 36 months
Time Frame
Ongoing for up to 36 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
59 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Inclusion Criteria Non pregnant women 35-59 years of age. No hysterectomy No prior pelvic radiation. Willing to sign consent form Exclusion Criteria: Males Women younger than 35 years old and older than 59 years old. Pregnant women. Patients with known history of hysterectomy or radiation for a pelvic cancer. Refusal to participate
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jerome L Belinson, MD
Organizational Affiliation
Preventive Oncology International
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Rufiang Wu, MD
Organizational Affiliation
Peking Universtiy Shenzhen Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
HeShan Public Health Department
City
Jiangmen Municipal City
State/Province
Guangdong
Country
China

12. IPD Sharing Statement

Citations:
PubMed Identifier
24440471
Citation
Belinson JL, Wang G, Qu X, Du H, Shen J, Xu J, Zhong L, Yi J, Yi X, Wu R. The development and evaluation of a community based model for cervical cancer screening based on self-sampling. Gynecol Oncol. 2014 Mar;132(3):636-42. doi: 10.1016/j.ygyno.2014.01.006. Epub 2014 Jan 14.
Results Reference
derived

Learn more about this trial

Chinese Cancer Prevention Study(CHICAPS)

We'll reach out to this number within 24 hrs